Background. Complements play important roles in both rejection and ischemia-reperfusion injury after transplantation. Complement 5 (C5) is a pivotal complement, which initiates the assembly of the membrane attack complex, and mediates chemotaxis of various immune cells. We investigated the impacts of genetic variations in C5 and its receptor (C5aR) of both recipients and donors on renal allograft outcomes. Methods. Seven single-nucleotide polymorphisms (SNPs) in C5 (rs12237774, rs2159776, rs17611, rs25681, rs2241004, rs10985126 and rs10818500) and one SNP (rs10404456) in the C5aR gene were genotyped in 191 recipient-donor pairs. The association of the polymorphisms with allograft outcomes was determined. Results. Three C5 SNPs (rs2159776, rs17611 and rs25681) in recipients had a tendency toward a reduced glomerular filtration rate at 1 year after transplantation. There were four haplotypes in the H2 linkage disequilibrium block, which was formed by four SNPs (rs2159776, rs17611, rs25681 and rs2241004). The GGCG haplotype in both recipients and donors was associated with lower glomerular filtration rate at 1 year (60.9 6 15.9 versus 66.4 6 15.5 mL/min/1.73m 2 , P ¼ 0.020; 60.6 6 15.3 versus 66.2 6 15.8 mL/min/1.73m 2 , P ¼ 0.017). The association was sustained over 7 years after transplantation (P ¼ 0.015 in recipients; P ¼ 0.039 in donors). The presence of the GGCG haplotype in recipients was associated with poorer graft survival (logrank test, P ¼ 0.024). However, C5 polymorphisms were not correlated with serum C5 level. C5aR polymorphism had no significant impact on the allograft outcomes. Conclusions. The GGCG haplotype of C5 in both recipients and donors was associated with lower renal allograft function. 
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Introduction
Complements are important humoral effectors in innate immunity and they can also play the role of a link between innate and adaptive immune responses [1] . Therefore, they can contribute to tissue injury such as ischemia-reperfusion injury (IRI) [2] [3] [4] , humoral rejection or acute cellular rejection [5, 6] in transplantation. Ischemia lowers the resistance of endothelial cells to complement attack and exposes the activating surface to complements. Beyond IRI, complements act as effectors in hyperacute, acute and chronic humoral rejection, and C4d deposition is included in the diagnostic criteria for humoral rejection [7] . Both complement 3 (C3) and 5 (C5) can provide co-stimulation in the interaction between dendritic cells and T cells, thereby contributing to acute cellular rejection [6, 8] .
Three complement activation pathways (the classical, alternative and mannose-binding lectin pathways) converge in the cleavage of C3. C3b participates in the formation of C5 convertase, which cleaves C5 into C5a and C5b. C5b forms the membrane attack complex (C5b-C9), a humoral effector. C5a mediates the immune reaction via chemotaxis and cell activation through interaction with its cognate receptor (C5aR) [9] [10] [11] . C5aR is present on neutrophils, T cells, B cells, epithelial cells and endothelial cells [12] . C5a-C5aR interaction in antigen presenting cells and T cells can provide co-stimulatory and survival signals to naive CD4 T cells, which induce upregulation of antigen-specific T-cell responses [13] . The CD81 T-cell response to influenza type A virus was impaired when mice were treated with C5aR antagonist [14] . C5 also regulates adaptive immunity by the modulation of dendritic cell function [8] . There is increasing evidence from animal experiments, where antagonists of C5 or C5aR showed protective effects against IRI [3, 4, 15, 16] . Moreover, anti-C5 monoclonal antibodies have been developed as therapeutic antibodies and have performed promisingly in clinical trials for paroxysmal nocturnal hemoglobinuria [17] and transplantation [18] [19] [20] [21] .
Consistent with the importance of complements in transplantation, recent studies have reported the association between polymorphisms of complement genes and clinical outcomes of kidney allograft recipients [22] [23] [24] . Among >30 proteins in the complement system, the C3 had received focus because it is in the central part of the complement cascades and its allotypic variants (C3F and C3S) are well known. However, its minor allele frequency (MAF) is <1% in Asian populations [25] . Therefore, we focused on C5, another important complement immediately downstream of C3. Herein, we investigated the association of C5/C5aR gene polymorphisms with renal allograft outcomes.
Materials and methods

Study population
Three hundred and eighty-two adult patients (recipient age > 18 years) underwent living donor kidney transplantation at the Seoul National University Hospital (SNUH) from January 1996 to February 2007. Among them, DNA samples were available with informed consent for genetic analysis in 191 donor-recipient pairs. There was no significant difference in baseline clinical characteristics between the 191 participants and the non-participants, except the choice of initial calcineurin inhibitor (data not shown). The study protocols were approved by the Institutional Review Board of SNUH (H-0802-059-235). All study processes were conducted under the Declaration of Helsinki.
Genotyping
Linkage disequilibrium (LD) blocks of the C5 gene were constructed based on single-nucleotide polymorphisms (SNPs) genotyped in the HapMap Asian JPT1CHB samples (www.hapmap.org). A total of 75 SNPs were genotyped in~110-kb region including C5 gene (9q34.1) and its 5# upstream. SNPs with an MAF of <5% were excluded. We predicted four LD blocks using the confidence interval (CI) method in Haploview 4.1 [26] (Supplementary Figure 1A) . Within each haplotype block, haplotype-tagging SNPs (htSNPs) (rs12237774, rs2159776, rs2241004, rs10985126 and rs10818500) were chosen so that any marker in the LD blocks was presumed to be correlated with htSNPs with r 2 > 0.8. In addition, two SNPs (rs17611 and rs25681) were added because they were significantly associated with asthma in Japanese [27] . One SNP (rs10404456) was selected in the C5aR gene (19q13.3) because it was completely linked to the other SNPs.
Genotyping was performed using TaqMan SNP Genotyping Assays, according to the manufacturer's instructions.
Clinical data analysis
Clinical information was retrieved from the SNUH transplantation database, which includes demographic data on donor and recipient, number of Human Leukocyte Antigen (HLA) mismatches, initial immunosuppressant regimen, cause of end-stage renal disease (ESRD), comorbid status of diabetes mellitus, presence of biopsy-proven acute rejection, serum creatinine levels and transplantation outcomes. 
Determination of C5 level
In order to assess the functional significance of C5 haplotypes, we determined serum C5 levels and genotypes in 100 healthy subjects. Serum C5 concentration was measured using a commercial radial immunodiffusion kit (The Binding Site, Birmingham, UK). The mean age of subjects was 43.1 AE 7.2 years and male-to-female ratio was 1.3 (M:F ¼ 56:44).
Statistical analysis
Calculated power of our study for common SNPs with MAF of >40% (rs2159776, rs17611, rs25681 and rs10404456) exceeded 80% to detect a difference of 5 mL/min/1.73m 2 in eGFR between genotype groups. For less common SNPs with 25% MAF (rs2241004) or 15% MAF (rs1223774, rs10985126 and rs10818500), powers were 73 and 65%, respectively. In haplotype analysis using H2 locus, the statistical power of our study was 88% to detect a difference of eGFR. One-way analysis of variance or the t-test was used for the analysis of continuous variables, and the chi-square test or Fisher's exact test was performed for the categorical variables, as appropriate. Association of the C5/C5aR genotype/haplotype with 1-year graft function was analyzed using multiple linear regression analysis (backward stepwise method). Generalized estimating equations (GEEs) were used for analyzing the association of C5 haplotypes with graft function during the 7 years after transplantation [28] . Genotypes or haplotypes that were significantly associated with graft function were tested in the model with an exchangeable working correlation matrix. Covariates were retained if Wald's P-value was <0.05. Association of C5 haplotypes with graft survival was analyzed using the logrank test. Cox proportional hazard regression was used for multivariate analysis. Statistical analyses were performed using the SPSS statistical package version 17.0 (SPSS Inc, Chicago, IL) and PLINK version 1.05 (http://pngu.mgh.harvard.edu/purcell/ plink/) [29] .
Results
Baseline clinical characteristics of study population
The mean age of recipients at the time of transplantation was 40 AE 11.8 years and that of donors was 38 AE 11.1 years. The proportions of male gender in recipients and donors were 63.4 and 50.8%, respectively. The mean number of HLA mismatches was 2.8 AE 1.6. The proportion of living unrelated donors was 25.7%. Preemptive transplantation was performed in 15.7% of cases. Four cases (2.1%) had a history of previous renal transplantation. Two cases of transplantation were performed under a desensitization protocol because of positive T-cell flow cytometric crossmatch results. The standard immunosuppressive regimen consisted of prednisolone, calcineurin inhibitors and antimetabolites. Tacrolimus was used as initial immunosuppressant in 30.9% of patients. Azathioprine was replaced by mycophenolate mofetil beginning in 2000. Divided by antimetabolites era, 33% of transplantation had been performed before 2000. The most common cause of ESRD was glomerulonephritis (40.3%), followed by hypertension (13.1%), diabetes mellitus (7.3%) and unknown causes (31.4%).
Genotyping and construction of LD blocks
All tested SNPs of C5 and C5aR were in Hardy-Weinberg equilibrium. Genotyping failure rates were <4% in all SNPs (Supplementary Table 1 ). Four LD blocks were constructed in the C5 gene and were designated as H1, H2, H3 and H4. The H2 block consisted of four SNPs (rs2159776, rs17611, rs25681 and rs2241004) (Supplementary Figure 1A) .
Association of C5/C5aR genotypes of recipients/donors with acute rejection
Acute rejection occurred in 44 cases (23.0%) during the follow-up period (mean, 87.7 AE 41.8 months). Most acute rejections (93.2%) were cellular rejection, except three cases of acute humoral rejection. The genotype distributions of C5/C5aR in both recipients and donors were analyzed according to the occurrence of acute rejection (Supplementary Table 2 ). Two C5 SNPs (rs10985126 and rs10818500) of the recipients showed an association with acute rejection (P ¼ 0.034 for rs10985126 and P ¼ 0.009 for rs10818500); however, their significance was lost after Bonferroni's correction for multiple comparison. C5aR genotypes of recipients were not associated with acute rejection. There was also no statistically significant association between donor C5/C5aR genotypes and acute rejection (Supplementary Table 2 ).
Association of C5/C5aR genotypes/haplotypes of recipients/donors with graft function eGFR at 1 year after transplantation was compared according to the C5 and C5aR genotypes of the recipients and donors (Table 1) . Three C5 SNPs of the recipients were associated with graft function (P ¼ 0.012 for rs17611; P ¼ 0.010 for rs25681; P ¼ 0.012 for rs2241004). However, their significance was lost after Bonferroni's correction. Because the three SNPs belong to the H2 block, we analyzed the association of H2 haplotypes with graft function (Supplementary Table 3 ). The haplotype frequencies in the H2 block were as follows: 0.516, 0.269, 0.180 and 0.035 for AATA, GGCG, GGCA and rare haplotypes of which frequencies were <0.05 (AGCA, GATA and AGTA), respectively. The GGCG haplotype was significantly associated with lower 1-year eGFR (Supplementary Table 3 ). The GGCG haplotype of recipients was associated with eGFR under the dominant model (60.9 AE 15.9 versus 66.4 AE 15.5 mL/min/1.73m 2 , P ¼ 0.020, Table 2 ). Furthermore, this haplotype of donors was also significantly associated with graft function under the dominant model (60.6 AE 15.3 versus 66.2 AE 15.8 mL/min/1.73m 2 , P ¼ 0.017, Table 2 ). When recipients were paired with donors according to the GGCG haplotype, four pairs were generated (D1/R1, D1/RÀ, DÀ/R1 and DÀ/RÀ). Other clinical variables were tested for the association with eGFR, which are presented in Table 3 . Variables with Pvalue <0.2 were considered as possible covariates, which included recipient age, donor age, donor gender, diabetes, choice of initial calcineurin inhibitor and acute rejection within 1 year after transplantation. Multiple linear regression analysis was performed with covariates. Pairs with the GGCG haplotype in both donor and recipient (D1/R1) were independently associated with reduced eGFR compared to pairs with the GGCG haplotype in neither the recipient nor donor (DÀ/RÀ) (P ¼ 0.012, Table 4 ). However, neither recipients' nor donors' C5aR SNP was associated with graft function.
Next, eGFR during the 7 years after transplantation was depicted according to the presence of the C5 GGCG haplotype in recipients or donors ( Figure 1A and B). The C5 Comparison of donor-recipient pairs that had received transplantation since 2000 against those who had transplantation during 1996-99.
C5 polymorphism and renal allograft outcomerisk haplotype of both recipients and donors was associated with a lower eGFR (R1 versus RÀ, P ¼ 0.015; D1 versus DÀ, P ¼ 0.039; multivariate GEE, Table 5 ). The presence of the C5 GGCG haplotype in donor-recipient pairs (D1/R1 versus DÀ/RÀ) was significantly associated with reduced eGFR independently (P ¼ 0.004), along with acute rejection (P <0.001), and donor age (P ¼ 0.01) ( Figure 1C , Table 6 ). Taken together, these data demonstrated that C5 polymorphisms in both donor and recipient had a significant impact on renal allograft function.
Association of C5/C5aR haplotypes of recipients/donors with graft survival
A total of 15 patients (7.9%) lost their allografts. Death occurred in six patients. Overall, the 10-year cumulative death-censored graft and patient survival rate were 96.1 and 89.8%, respectively. Recipients with the C5 GGCG haplotype had poorer graft survival under the dominant model (logrank test, P ¼ 0.024, Figure 2A) . However, donor GGCG haplotype did not show any association with graft survival (P ¼ 0.092, Figure 2B ). When we compared graft survival by the combination of recipient and donor GGCG haplotype, D1/R1 donor-recipient pairs had a poorer graft survival compared with DÀ/RÀ pairs [Hazard Ratio (HR) 3.581, 95% CI 1.100-11.659, P ¼ 0.034, Figure 2C ]. When multivariate analysis was performed by Cox regression, the HR of the C5 GGCG haplotype (D1/R1 versus DÀ/ RÀ) was 2.941 (95% CI 0.890-9.719, P ¼ 0.077) after adjusting for acute rejection (HR 8.602, 95% CI 2.980-24.831, P < 0.001) and the use of tacrolimus as an initial immunosuppression regimen (HR 0.137, 95% CI 0.018-1.039, P ¼ 0.055). C5aR polymorphism was not associated with graft survival.
Association of C5/C5aR haplotypes with serum C5 level
The mean serum C5 concentration in 100 healthy volunteers was 188.3 AE 38.5 mg/L (range, 83.0-283), which was Comparison of donor-recipient pairs that had the GGCG haplotype in both donor and recipient (D1/R1) against those that had the GGCG haplotype in neither donor nor recipient (DÀ/RÀ). not correlated with either age or gender. When the association between serum C5 level and H2 haplotype was analyzed, there was no significant association (data not shown).
Discussion
C5 plays a role in both humoral and cellular rejection through membrane attack complex formation, chemotaxis and co-stimulation. Consistent with the importance of C5 in transplantation, we demonstrated for the first time that C5 genetic polymorphisms in kidney transplantation were significantly associated with allograft function. Patients with the risk C5 haplotype (GGCG) had lower graft function during the 7 years after transplantation. However, there was no significant association between this haplotype and acute rejection. Complement production in the kidney allograft seems to continue even without overt histologic injury including acute rejection. Complement gene expression increased in allograft biopsies obtained 3-24 months after kidney transplantation compared to that in biopsies at the time of implantation [30] . These data suggest that complements might influence long-term graft outcomes. Two recent animal experiments have shown that complements can mediate renal tubulointerstitial fibrosis. Tubular epithelial cells exposed to C3a, expressed phenotypic and functional characteristics of epithelial-to-mesenchymal transition (EMT) [31] . Treatment with C3a receptor antagonist prevented C3a-induced EMT. The evidence for EMT, including the deposition of interstitial type I collagen and accumulation of myofibroblasts, was significantly lower in C3aR-deficient mice [31] . C5 knockout mice also showed ameliorated renal fibrosis in an experimental nonproteinuric renal damage model [32] . C5a receptor antagonist treatment to wild-type mice reduced renal fibrosis, which suggested that the interaction of C5a with C5aR seemed to be a key mediator of renal fibrosis [32] . C5 was also reported to modify liver fibrogenesis [33] . Therefore, the association of C5 with allograft function might be explained by its impact on renal fibrosis regardless of overt acute rejection. However, we could not compare the degree of interstitial fibrosis or tubular atrophy according to the C5 haplotypes for lack of protocol biopsy data. On the other hand, we cannot exclude the possibility that C5 might influence repeated subclinical rejection because we did not perform protocol biopsy [34] . Further studies using the protocol biopsy in a deceased donor kidney transplantation setting could be helpful for clearer interpretation because complement activation could have a greater impact on acute rejection in this setting with marked IRI and a larger number of HLA mismatch. Although complements are primarily produced in the liver, the kidney also produces complements [11, 35] . C3 can be produced by glomerular and tubular epithelial cells, mesangial cells and endothelial cells. Therefore, C3 derived from donor kidney cells contributes to allograft rejection [6, 35, 36] . Furthermore, C3 polymorphism of donors was associated with allograft survival in human kidney transplantation [23] . However, impact of the C3 polymorphism on graft outcomes is still controversial because another large-scale study failed to confirm the association of C3 fast-slow polymorphism with long-term graft outcome [24] . Despite that, local synthesis of C5 from renal epithelial cells has not been reported to date, antigenpresenting cells and T cells on activation can produce C5 in a paracrine manner [13, 37] . Therefore, local concentration of C5 might be elevated in renal allograft tissue, and high C5 activity could contribute to rejection or renal fibrosis [9] [10] [11] [12] [13] [14] [15] [16] 32] . In parallel, our data showed that C5 polymorphisms of donors as well as those of recipients were significantly associated with allograft function. D1/R1 donor-recipient pairs had lower graft function over 7 years compared with DÀ/RÀ pairs. The importance of donor polymorphisms suggests that donor-derived C5 in addition to recipient-derived C5 might play a role in allograft injury.
Patients with the risk haplotypes had lower graft survival, although multivariate analysis did not support independent influence of the risk haplotypes on graft survival after adjustment for other significant factors such as acute rejection. The survival difference between D1/R1 and DÀ/RÀ pairs was not statistically significant. The discrepancy between results on the graft survival and allograft function might be explained by the relatively short follow-up period and low occurrence rate of graft loss in our study for living donor kidney transplantation.
The C5 gene is 100 kb long and is located on chromosome 9. The risk polymorphisms associated with allograft outcomes in our study reside in the H2 locus of the C5 gene, which encompasses exons 12-28. They correspond to a part of the C5 beta chain, C5a, and a part of the C5 alpha chain (Supplementary Figure 1B) . Among four SNPs in the H2 locus, rs17611 is a nonsysnonymous SNP (Ile802Val ); however, it is a hydrophobic residue, located in the inner side of C5. Therefore, substitution of Ile802 by valine does not seem to induce critical structural changes in C5 (by PolyPhen; http://genetics .bwh.harvard.edu/pph/). Therefore, we postulated that the risk polymorphisms might be linked with another polymorphism that can affect the transcriptional level of the C5 gene. A previous study reported that when both the C5 level and haplotype-tagging polymorphisms of the C5 gene were determined in healthy subjects, C5 levels were significantly higher in individuals with risk C5 genotypes (A allele of rs17611) [33] . However, our study failed to replicate the difference in C5 levels according to genotype/haplotype possibly because of the method of C5 measurement or the difference in genotyped SNPs. On the other hand, serum C5 concentration might not reflect the local concentration of C5 in the allograft, which could be more important in allograft outcomes. Further studies are needed to determine the functional significance of the risk polymorphisms.
In summary, C5 polymorphism in both recipients and donors was significantly associated with allograft function over 7 years after kidney transplantation, whereas C5aR polymorphism had no significant impact on the allograft outcomes.
Supplementary data
Supplementary data is available online at http:// ndt.oxfordjournals.org.
Acknowledgements. This work was accepted for the presentation in XXIII International Congress of The Transplantation Society (Vancouver, Fig. 2 . Kaplan-Meier estimates of graft survival according to the C5 GGCG haplotype of recipients (A), donors (B) and donor-recipient pairs (C). The presence of recipient GGCG haplotype was associated with a poorer graft survival rate (logrank test, P ¼ 0.024). However, the GGCG haplotype of donors showed no association with graft survival rate (P ¼ 0.092). D1/R1 donor-recipient pairs had a poorer graft survival compared with DÀ/RÀ pairs (HR 3.581, 95% CI 1.100-11.659, P ¼ 0.034). The median duration of follow-up was 79 months. The numbers below the figure denote the number of subjects at risk in each group according to the GGCG haplotype during 7 years.
